23-valent pneumococcal polysaccharide vaccine is named as a drug or biological intervention in 4 clinical trials in our China, UK, USA and India trial registers, 2 of which are recruiting. Lead sponsors include Novartis Pharmaceuticals (1), Aimei Vacin BioPharm (Zhejiang) Co., Ltd. (1) and Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (1). Registered phases: Phase 3 and Phase 1/2. Conditions studied include Relapsing Multiple Sclerosis; Pneumococcal Disease; Healthy Volunteers.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06044077 | A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People (ClinicalTrials.gov ↗) Pneumococcal Disease |
Phase 3 | Recruiting |
| NCT07600983 | Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (ClinicalTrials.gov ↗) Streptococcus Pneumoniae Infection |
Phase 1/2 | Recruiting |
| NCT03650114 | Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ClinicalTrials.gov ↗) Relapsing Multiple Sclerosis |
Phase 3 | Active, closed |
| NCT06314867 | Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23 (ClinicalTrials.gov ↗) Healthy Volunteers |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Relapsing Multiple Sclerosis | 1 |
| Pneumococcal Disease | 1 |
| Healthy Volunteers | 1 |
| Streptococcus Pneumoniae Infection | 1 |
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 1 |
| Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | 1 |
| Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 1 |
| CanSino Biologics Inc. | 1 |
| Register | 23-valent pneumococcal polysaccharide vaccine trials |
|---|---|
| Clinical trials in China | 3 |
| Clinical trials in UK | 1 |
| Clinical trials in USA | 1 |
| Clinical trials in India | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how 23-valent pneumococcal polysaccharide vaccine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists 23-valent pneumococcal polysaccharide vaccine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.